Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 145Head & Neck 18Breast 12Tumor-Agnostic 5Gynecologic 4Dermatologic 4Thoracic 3Other solid neoplasm 3Genitourinary 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Endocrine 2Plasma cell 1Other 1NET 1Myeloid 1Classical hematology 1

Conditions

Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3lanreotide 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Octreotide 2Magnetic Resonance Spectroscopy 2Filgrastim 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1folfirinox 1famitinib 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fluorouracil × NET × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡